Drug Profile
AUR 1001
Alternative Names: OX-1406Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator OncoNOX
- Developer Aura Biopharm
- Class Monoclonal antibodies
- Mechanism of Action Glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Antiphospholipid syndrome
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Antiphospholipid syndrome in USA (unspecified route) (Aura Biopharm, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Antiphospholipid-syndrome in USA
- 03 Aug 2016 Preclinical trials in Antiphospholipid syndrome in USA (unspecified route) prior to August 2016